Why the BARD1 (ASX:BD1) share price plummeted 9% today

The BARD1 Life Sciences Ltd share price has sunk 9% despite announcing a positive update. We take a closer look at what the company released.

The BARD1 Life Sciences Ltd (ASX: BD1) share price had a woeful day on the ASX today. This comes despite the company releasing positive results for its novel pan-cancer probe, SubB2M-based immunohistochemistry (IHC) test.

At market close, BARD1 shares finished the day at $2.19, down 9.5%.

SubB2M is an engineered protein that binds to a unique sugar molecule called Neu5Gc. This protein is only present in human cancers. Additionally, it can detect the disease using liquid biopsies, immunoassays, circulating tumour cell assays, and PET imaging.

A businessman holds his glasses in concern, indicating uncertainly in the ASX share price

Image source: Getty Images

What did BARD1 announce?

Investors are selling BARD1 shares despite receiving promising results from a preliminary study demonstrating the feasibility of its SubB2M technology.

In its announcement, BARD1 advised that SubB2M has successfully been used to demonstrate staining of cancer in specific tissue sections. The preliminary study compared cancer tissue from an invasive ductal breast cancer tumour biopsy against a non-cancer breast tissue biopsy.

The study also found that the SubB2M IHC test could be performed on automated staining equipment. This equipment is used in pathology laboratories worldwide. BARD1 noted that once the staining has been optimised for breast cancer tissue. It will extend its studies to other cancer applications.

The company noted that its SubB2M-based IHC applications represent a potential fast-to-market product opportunity.

BARD1 CSO, Dr Peter French welcomed the results, saying:

Whilst this data is from a single patient sample, and the assay conditions have not been optimised, we are pleased that we were able to utilise SubB2M to achieve a positive staining outcome in breast cancer FFPE sections. This is the first time SubB2M has been used in a histopathology application, and it demonstrated both initial feasibility in an IHC application for breast cancer and compatibility with an automated staining instrument.

BARD1 CEO, Dr Leearne Hinch added:

This initial feasibility data indicates that our SubB2M technology may be expanded to IHC applications for tissue-based cancer diagnosis. This represents a potential fast- to-market product opportunity for BARD1's expanding cancer diagnostic pipeline. The global immunohistochemical market was valued at US$1.8 billion in 2019 and SubB2M-based IHCs could be developed for cancers such as melanoma where it can be difficult to distinguish malignant from benign tissues.

About the BARD1 share price

In the past 12 months, BARD1 shares have accelerated to more than 180%. However, year-to-date performance has further jumped to post a gain above 220%.

Based on valuation metrics, BARD1 presides a market capitalisation of roughly $175 million, with approximately 80 million shares outstanding.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Share Fallers

Codan share price A dismayed kid dressed as a scientist stands with his back to a rocket crashed into the ground
Share Fallers

Xero shares crash to a 7-year low after a brutal sell-off

The decline has wiped out years of share price gains.

Read more »

Two miners at a mine site on their tablets, with mining machinery behind them.
Share Fallers

Why has the Mineral Resources share price fallen 12% this week?

It’s been another tough week for Mineral Resources shareholders.

Read more »

A man holds his hand to his chin with a furrowed brow, making an expression of puzzlement or confusion.
Share Fallers

Top 3 ASX 200 shares now below their 200-day moving average

Are these businesses still a buy?

Read more »

A young man clasps his hand to his head with a pained expression on his face and a laptop in front of him.
Share Fallers

What are the most shorted ASX shares on the market right now?

Two names, two opposite bear cases.

Read more »

An arrow crashes through the ground as a businessman watches on.
Share Fallers

Warning: Corporate Travel shares have crashed 80%. What on earth just happened?

An 80% crash has left investors asking what went so wrong.

Read more »

Stressed businessman sits in panic amid digital stock market financial background.
Share Fallers

The five worst-performing ASX 200 shares in August unmasked

Investors sent these five ASX shares crashing 17% to 23% in August. But why?

Read more »

Stressed businessman sits in panic amid digital stock market financial background.
Share Fallers

Why Megaport, Lendlease and JB Hi-Fi shares all crashed 14% to 15% this week

ASX investors punished Lendlease, Megaport, and JB Hi-Fi this week. But why?

Read more »

Woman checking out new laptops.
Consumer Staples & Discretionary Shares

Down 14% today: Are JB Hi-Fi shares now a bargain-bin buy?

Could JB's plunge mean a bargain buy?

Read more »